<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00144248</url>
  </required_header>
  <id_info>
    <org_study_id>1100.1448</org_study_id>
    <nct_id>NCT00144248</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions</brief_title>
  <official_title>A Pharmacokinetic Study to Assess Nevirapine Levels in HIV-infected Patients With Impaired Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the steady-state clearance of nevirapine among&#xD;
      HIV-1 positive patients with hepatic fibrosis, and to examine whether the degree of hepatic&#xD;
      impairment influences clearance.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoints are the degree of hepatic impairment, steady state nevirapine clearance, and the increase in estimated clearance when trough is supplemented by plasma levels measured one, two and four hours after nevirapine administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of nevirapine metabolites of all patients and Child-Pugh scores among patients with cirrhosis.</measure>
  </secondary_outcome>
  <enrollment type="Actual">51</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hepatic Insufficiency</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nevirapine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION&#xD;
&#xD;
          1. Male or female subjects &gt;=18 years of age with HIV-1 infection and chronic liver&#xD;
             disease as reflected by a documented biopsy with hepatic fibrosis present.&#xD;
&#xD;
          2. a. Participants must be receiving nevirapine 200 mg twice daily as part of a stable&#xD;
             ARV regimen for a minimum of 6 weeks prior to trough level sample collection.&#xD;
&#xD;
             b. Participants receiving nevirapine 400 mg once daily as part of a stable ARV regimen&#xD;
             for a minimum of 6 weeks, who are willing to switch to nevirapi0 mg twice daily for a&#xD;
             minimum of 14 days prior to trough collection.&#xD;
&#xD;
          3. Participants must have uoxylin and Eosin (H and E) stained slide and one trichrome&#xD;
             stained pathology slide available at the time of enrollment. There is no time&#xD;
             restriction on liver biopsy slides that pathologically confirm the presence of&#xD;
             cirrhosis. The presence of cirrhosis must be documented on the liver biopsy report.&#xD;
&#xD;
        EXCLUSION&#xD;
&#xD;
          1. Current (within the past 4 weeks) HIV antiviral therapy with other NNRTI's.&#xD;
&#xD;
          2. Concurrent use (within the past 7 days) of any of the following:&#xD;
&#xD;
               1. Systemic azole antifungal agents (fluconazole, itraconazole, ketoconazole, etc.)&#xD;
&#xD;
               2. Clarithromycin&#xD;
&#xD;
               3. Rifampin&#xD;
&#xD;
               4. St John's Wort&#xD;
&#xD;
          3. Inability to provide a blood sample.&#xD;
&#xD;
          4. Patients who have evidence for hepatic or other encephalopathy above Grade 1&#xD;
&#xD;
          5. Patients with renal failure who require dialysis.&#xD;
&#xD;
          6. Pregnant and/or breast feeding women..&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College, MC 142</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de l'Hotel Dieu</name>
      <address>
        <city>Lyon cedex 02</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico y Provincial de Barcelona - HIV</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1448_U06-3702.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1100/1100.1448_literature.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/19620337</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2005</study_first_posted>
  <last_update_submitted>December 27, 2017</last_update_submitted>
  <last_update_submitted_qc>December 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nevirapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

